Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population PK/PD analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
ChiCTR2100046685Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in nonvalvular atrial fibrillation (NVAF) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Rivaroxaban plasma concentration, Anti-factor Xa activity and 3 more. Started Jun 2021; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on ChiCTR2100046685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046685.